S&P 500   4,335.54 (+0.21%)
DOW   34,049.59 (-0.33%)
QQQ   341.04 (-0.02%)
AAPL   165.45 (+3.91%)
MSFT   298.53 (-0.44%)
FB   294.24 (-0.14%)
GOOGL   2,581.22 (+0.04%)
AMZN   2,774.72 (-0.65%)
TSLA   838.71 (+1.16%)
NVDA   217.43 (-0.92%)
BABA   110.73 (-0.95%)
NIO   20.08 (-4.88%)
AMD   101.90 (-0.68%)
CGC   6.89 (+0.58%)
MU   76.54 (-2.77%)
GE   89.35 (-0.61%)
T   24.34 (+0.91%)
F   19.12 (-2.20%)
DIS   134.71 (-0.52%)
AMC   13.82 (-4.82%)
PFE   53.78 (+0.77%)
ACB   3.77 (-0.53%)
BA   184.26 (-2.89%)
S&P 500   4,335.54 (+0.21%)
DOW   34,049.59 (-0.33%)
QQQ   341.04 (-0.02%)
AAPL   165.45 (+3.91%)
MSFT   298.53 (-0.44%)
FB   294.24 (-0.14%)
GOOGL   2,581.22 (+0.04%)
AMZN   2,774.72 (-0.65%)
TSLA   838.71 (+1.16%)
NVDA   217.43 (-0.92%)
BABA   110.73 (-0.95%)
NIO   20.08 (-4.88%)
AMD   101.90 (-0.68%)
CGC   6.89 (+0.58%)
MU   76.54 (-2.77%)
GE   89.35 (-0.61%)
T   24.34 (+0.91%)
F   19.12 (-2.20%)
DIS   134.71 (-0.52%)
AMC   13.82 (-4.82%)
PFE   53.78 (+0.77%)
ACB   3.77 (-0.53%)
BA   184.26 (-2.89%)
S&P 500   4,335.54 (+0.21%)
DOW   34,049.59 (-0.33%)
QQQ   341.04 (-0.02%)
AAPL   165.45 (+3.91%)
MSFT   298.53 (-0.44%)
FB   294.24 (-0.14%)
GOOGL   2,581.22 (+0.04%)
AMZN   2,774.72 (-0.65%)
TSLA   838.71 (+1.16%)
NVDA   217.43 (-0.92%)
BABA   110.73 (-0.95%)
NIO   20.08 (-4.88%)
AMD   101.90 (-0.68%)
CGC   6.89 (+0.58%)
MU   76.54 (-2.77%)
GE   89.35 (-0.61%)
T   24.34 (+0.91%)
F   19.12 (-2.20%)
DIS   134.71 (-0.52%)
AMC   13.82 (-4.82%)
PFE   53.78 (+0.77%)
ACB   3.77 (-0.53%)
BA   184.26 (-2.89%)
S&P 500   4,335.54 (+0.21%)
DOW   34,049.59 (-0.33%)
QQQ   341.04 (-0.02%)
AAPL   165.45 (+3.91%)
MSFT   298.53 (-0.44%)
FB   294.24 (-0.14%)
GOOGL   2,581.22 (+0.04%)
AMZN   2,774.72 (-0.65%)
TSLA   838.71 (+1.16%)
NVDA   217.43 (-0.92%)
BABA   110.73 (-0.95%)
NIO   20.08 (-4.88%)
AMD   101.90 (-0.68%)
CGC   6.89 (+0.58%)
MU   76.54 (-2.77%)
GE   89.35 (-0.61%)
T   24.34 (+0.91%)
F   19.12 (-2.20%)
DIS   134.71 (-0.52%)
AMC   13.82 (-4.82%)
PFE   53.78 (+0.77%)
ACB   3.77 (-0.53%)
BA   184.26 (-2.89%)
NASDAQ:AVTX

Avalo Therapeutics Stock Forecast, Price & News

$0.86
-0.03 (-3.65%)
(As of 01/28/2022 10:42 AM ET)
Add
Compare
Today's Range
$0.85
$0.87
50-Day Range
$0.82
$2.22
52-Week Range
$0.78
$4.50
Volume
1,843 shs
Average Volume
998,004 shs
Market Capitalization
$96.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.64
30 days | 90 days | 365 days | Advanced Chart
Receive AVTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Avalo Therapeutics logo

About Avalo Therapeutics

Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVTX
Fax
N/A
Employees
31
Year Founded
N/A

Sales & Book Value

Annual Sales
$6.70 million
Book Value
$0.33 per share

Profitability

Net Income
$-63.50 million
Net Margins
-1,211.01%
Pretax Margin
-1,224.54%

Debt

Price-To-Earnings

Miscellaneous

Free Float
60,989,000
Market Cap
$96.30 million
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
1/28/2022
Next Earnings (Estimated)
3/14/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.83 out of 5 stars

Medical Sector

40th out of 1,417 stocks

Pharmaceutical Preparations Industry

12th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -












Avalo Therapeutics (NASDAQ:AVTX) Frequently Asked Questions

Is Avalo Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Avalo Therapeutics stock.
View analyst ratings for Avalo Therapeutics
or view top-rated stocks.

Are investors shorting Avalo Therapeutics?

Avalo Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 1,990,000 shares, an increase of 28.4% from the December 31st total of 1,550,000 shares. Based on an average daily trading volume, of 506,100 shares, the short-interest ratio is currently 3.9 days. Approximately 1.8% of the company's shares are sold short.
View Avalo Therapeutics' Short Interest
.

When is Avalo Therapeutics' next earnings date?

Avalo Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for Avalo Therapeutics
.

How were Avalo Therapeutics' earnings last quarter?

Avalo Therapeutics Inc (NASDAQ:AVTX) posted its earnings results on Tuesday, November, 9th. The company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.01. The firm earned $1.35 million during the quarter. Avalo Therapeutics had a negative trailing twelve-month return on equity of 272.08% and a negative net margin of 1,211.01%.
View Avalo Therapeutics' earnings history
.

What price target have analysts set for AVTX?

2 equities research analysts have issued 1 year price targets for Avalo Therapeutics' shares. Their forecasts range from $5.00 to $6.00. On average, they expect Avalo Therapeutics' share price to reach $5.50 in the next year. This suggests a possible upside of 541.5% from the stock's current price.
View analysts' price targets for Avalo Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Avalo Therapeutics' key executives?

Avalo Therapeutics' management team includes the following people:
  • Michael F. Cola, Chief Executive Officer & Director
  • Schond L. Greenway, Chief Financial Officer & Treasurer
  • H. Jeffrey Wilkins, Chief Medical Officer
  • Garry Arthur Neil, Chief Scientific Officer
  • Younok Dumortier Shin, Chief Technology Officer

What is Avalo Therapeutics' stock symbol?

Avalo Therapeutics trades on the NASDAQ under the ticker symbol "AVTX."

Who are Avalo Therapeutics' major shareholders?

Avalo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Strs Ohio (0.03%) and Minot Wealth Management LLC (0.03%). Company insiders that own Avalo Therapeutics stock include Armistice Capital, Llc, Christopher Ryan Sullivan, H Jeffrey Wilkins and Schond L Greenway.
View institutional ownership trends for Avalo Therapeutics
.

Which major investors are selling Avalo Therapeutics stock?

AVTX stock was sold by a variety of institutional investors in the last quarter, including Minot Wealth Management LLC, and Strs Ohio.
View insider buying and selling activity for Avalo Therapeutics
or view top insider-selling stocks.

How do I buy shares of Avalo Therapeutics?

Shares of AVTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avalo Therapeutics' stock price today?

One share of AVTX stock can currently be purchased for approximately $0.86.

How much money does Avalo Therapeutics make?

Avalo Therapeutics has a market capitalization of $96.30 million and generates $6.70 million in revenue each year.

How many employees does Avalo Therapeutics have?

Avalo Therapeutics employs 31 workers across the globe.

What is Avalo Therapeutics' official website?

The official website for Avalo Therapeutics is www.cerecor.com.

Where are Avalo Therapeutics' headquarters?

Avalo Therapeutics is headquartered at 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713.

How can I contact Avalo Therapeutics?

Avalo Therapeutics' mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The company can be reached via phone at (410) 522-8707 or via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.